Conavi Medical Corp.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Thomas Looby
- Full Time Employees
- 46
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 293 Lesmill Road Toronto ON Canada M3B 2V1
- IPO Date
- Apr 28, 2008
- Website
- conavi.com
- Similar Companies
- Business
- Conavi Medical Corp. designs, manufactures, and markets intravascular imaging technologies for guiding minimally invasive cardiovascular procedures, with a focus on the Novasight Hybrid System that enables simultaneous intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging. The company’s products address coronary artery visualization during angioplasty and stenting, offering co-registered, high-resolution imaging that combines OCT’s detail with IVUS’s larger field of view. Conavi operates primarily in Canada and the United States, with a global strategy to expand adoption through clinician education, clinical validation, and regulatory milestones. Founded in 2014, and headquartered in Toronto, Ontario, Conavi maintains its core operations around research, development, manufacturing, and commercialization of image-guided interventional devices for cardiovascular care. Main products and services include the Novasight Hybrid System (IVUS-OCT catheter-based imaging platform), companion software for image co-registration and visualization, clinical validation publications, and regulatory clearance support for market introductions; ongoing partnerships with medical institutions and distributors to expand access; and after-market support services for imaging systems, training, and technical assistance. Latest major changes include FDA 510(k) clearance milestones for the Novasight Hybrid System with simultaneous IVUS-OCT capabilities in the United States, a public financing activity to strengthen the balance sheet, and strategic announcements detailing near-term U.S. market entry and ongoing clinical validation efforts; additional updates reference planned or executed U.S. market launches and expansion of product offerings within the interventional cardiology imaging space. Industry focus centers on medical devices, imaging technology, and cardiovascular interventions; target customers are interventional cardiologists, catheterization laboratories, and healthcare institutions seeking advanced intravascular imaging to guide PCI procedures; global operations span North America with potential expansion into additional international markets; corporate relationships include a parent company structure and subsidiary activities centered on Novasight product development and commercialization; the company’s innovations aim to establish a comprehensive portfolio of image-guidance solutions for cardiovascular procedures through continued regulatory approvals, clinical evidence, and surgeon adoption.
Company News
Conavi Medical Announces New Grants of Stock Options
Conavi Medical to Showcase FDA-Cleared Hybrid Imaging System at TCT 2026
Conavi Medical Announces Peer-Reviewed Case Report Highlighting Clinical Utility of Hybrid IVUS-OCT Imaging, and Provides Update on Management Team
Conavi Medical Announces Media and Digital Marketing Agreements
Conavi Medical Reports Fiscal Third Quarter 2026 Results and Operational Highlights
Conavi Medical Corp. Announces Closing of $10M Public Offering
Conavi Medical Corp. Announces Pricing of Public Offering of Common Shares and/or Pre-Funded Warrants
Conavi Medical Announces JSCAI Publication Demonstrating the Clinical Utility of Hybrid IVUS OCT Imaging
Conavi Medical Reports Fiscal Second Quarter 2026 Results and Operational Highlights
Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
Conavi Medical Awarded 2026 TAG Innovation Award
Conavi Medical to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
Conavi Medical Announces Results from Its Annual General Meeting of Shareholders
Conavi Medical Reports Fiscal First Quarter 2026 Results and Operational Highlights
Conavi Medical Highlights Peer-Reviewed Publication Demonstrating Advantages of Hybrid IVUS-OCT Imaging
Conavi Medical Corp. Announces Closing of $12M Public Offering
Conavi Medical Corp. Announces Filing of Amended & Restated Final Prospectus
Conavi Medical Reports Fiscal Year 2025 Results and Operational Highlights
Conavi Medical Corp. Announces Pricing of Public Offering of Common Shares and/or Pre-Funded Warrants
Conavi Medical Corp. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants